Sp62
INNOVATIONS IN MANAGEMENT OF BARRETT'S ESOPHAGUS
Date
May 18, 2024
Presenter
Mayo Clinic
Tracks
Related Products
JOURNEY TO COMPLETE REMISSION OF DYSPLASIA AND INTESTINAL METAPLASIA AFTER ENDOSCOPIC ERADICATION THERAPY OF BARRETT’S ESOPHAGUS RELATED DYSPLASIA AND ADENOCARCINOMA: A COMPARATIVE ANALYSIS OF ESD VS EMR RESULTS FROM A MULTICENTER NORTH AMERICAN COHORT
Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett’s esophagus (BE) related neoplasia. This prospective, European multicenter study (Euro-Coldplay, NTR NL7253) aimed to evaluate the efficacy and safety of FCBA for the treatment of limited BE…
AI Beyond the Endoscope: How AI is Revolutionizing GI Practice
This session looks at the rapidly growing applications and impacts of AI beyond endoscopy in the GI world, including office tools, scribes, billing resources, EHR tools etc…
RATES OF RECURRENT INTESTINAL METAPLASIA AND DYSPLASIA AFTER SUCCESSFUL ENDOSCOPIC THERAPY OF BARRETT'S NEOPLASIA BY CAP ASSISTED EMR VS ESD AND ABLATION: RESULTS FROM A LARGE NORTH AMERICAN MULICENTER COHORT
Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett’s esophagus (BE) related neoplasia. This prospective, European multicenter study (Euro-Coldplay, NTR NL7253) aimed to evaluate the efficacy and safety of FCBA for the treatment of limited BE…
INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
Background: Bile acids comprise a major component of refluxate in GERD, the major risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Bile acids are metabolized by bacteria, and bacterial composition is also impacted by exposure to bile acids…
